ASCO
Novartis drug shows cancer promise
June 5, 2013Research and Development, Sales and Marketing ASCO, Cancer, Novartis
A Novartis drug which has been given breakthrough therapy designation by the FDA has demonstrated early promise in patients with …
Promising signs for Novartis’ lung cancer drug
June 4, 2013Sales and Marketing ALK+, ASCO, LDK378, NSCLC, Novartis
Targeted lung cancer treatment LDK378 has been shown to help patients with the ALK+ gene mutation in a phase I trial.Novartis’ drug …
Merck Serono staff may strike over Geneva HQ closure
June 6, 2012Manufacturing and Production, Research and Development ASCO, Basel, Geneva, Merck Serono, Novartis, R&D
Workers at Merck Serono’s Swiss headquarters in Geneva have threatened industrial action over the company’s plans to shut down the …
Herceptin successor impresses at ASCO
June 6, 2012Research and Development, Sales and Marketing ASCO, Cancer, EMILIA, FDA, Roche, T-DM1
Roche’s new ‘smart bomb’ breast cancer drug T-DM1 has impressed at this year’s ASCO conference in Chicago. The trial showed it …
ASCO 2011: news from the front line against cancer
July 18, 2011Research and Development ASCO, Cancer, oncology
Pharmafocus presents selected highlights from the American Society of Clinical Oncology’s annual meeting in Chicago, beginning with non-small cell lung …
Roche impresses at ASCO with vemurafenib
June 6, 2011Research and Development, Sales and Marketing ASCO, Roche, skin cancer, vemurafenib
Roche’s vemurafenib has proven one of the stars of the ASCO cancer conference by increasing overall survival in skin cancer …
ASCO 2010: The Hedgehog Pathway and other ways to target cancer
August 19, 2010Research and Development ASCO, Cancer, thyroid cancer
The American Society of Clinical Oncology conference, one of the most important dates in the pharmaceutical industry’s calendar, took place …
Eisai’s breast cancer drug impresses at ASCO
June 9, 2010Research and Development ASCO, Eisai, Xeloda, eribulin
A new cancer drug developed by Japanese pharma company Eisai has shown promise in increasing overall survival rates in heavily …
Avastin promising in ovarian cancer
June 7, 2010Research and Development ASCO, avastin
Roche’s Avastin took a step closer to winning an additional indication after phase III trial data showed the blockbuster cancer …
ASCO cancer conference opens
June 4, 2010Research and Development ASCO, Cancer, lenalidomide, rituximab
One of the most important dates in the pharmaceutical industry’s calendar, the ASCO cancer conference begins today. The American Society …
ASCO 2009: advance of the blockbusters
June 18, 2009Sales and Marketing ASCO, Cancer
Key highlights of the recent American Society of Clinical Oncology's 45th Annual Meeting in Florida saw current blockbusters advance standard …
Don’t pick on medicines in health service downturn, says ABPI’s Barker
June 18, 2009Research and Development ASCO, Cancer
The UK's health service is heading for a severe financial shortfall and will have to consider limiting spending, including on …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
